KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Assets (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Assets for 11 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 1.04% to $2.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, up 1.04% year-over-year, with the annual reading at $2.3 billion for FY2025, 1.04% up from the prior year.
  • Assets hit $2.3 billion in Q4 2025 for CRISPR Therapeutics AG, up from $2.2 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $2.9 billion in Q2 2021 to a low of $2.0 billion in Q1 2021.
  • Historically, Assets has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2024.
  • Biggest five-year swings in Assets: surged 177.06% in 2021 and later fell 18.49% in 2022.
  • Year by year, Assets stood at $2.8 billion in 2021, then decreased by 18.49% to $2.2 billion in 2022, then fell by 0.6% to $2.2 billion in 2023, then grew by 0.56% to $2.2 billion in 2024, then rose by 1.04% to $2.3 billion in 2025.
  • Business Quant data shows Assets for CRSP at $2.3 billion in Q4 2025, $2.2 billion in Q3 2025, and $2.0 billion in Q2 2025.